RT Journal Article
SR Electronic
T1 Rapid displacement of SARS-CoV-2 variants within Japan correlates with cycle threshold values on routine RT-PCR testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.13.22273855
DO 10.1101/2022.04.13.22273855
A1 Wright, Danelle
A1 Chan, Carmen
A1 Chaochaisit, Wirawit
A1 Ogawa, Mio
A1 Tanaka, Junko
A1 Nozaki, Satoshi
A1 Narita, Shinji
A1 Shimizu, Eisuke
A1 Aoshima, Hideyuki
A1 Baran, Iri Sato
YR 2022
UL http://medrxiv.org/content/early/2022/04/16/2022.04.13.22273855.abstract
AB Background The rapid spread of SARS-CoV-2 worldwide has led to the emergence of new variants due to the presence of mutations that alter viral characteristics, but there have been few studies on trends in viral lineages in Japan, an island country. We hypothesized that changes in cycle threshold (Ct) values on reverse transcription polymerase chain reaction (RT-PCR) reflect the prevalent variants during a given period.Methods We performed next-generation sequencing of positive samples to identify the viral lineages in Japan in 2021 and compared variant prevalence with the average Ct values on routine RT-PCR using 4 primer sets.Results Based on 3 sequencing runs, the highly transmissible Alpha variant, which prevailed over other lineages, such as R.1, from April 2021, was dominated by the even stronger Delta variant between July and August 2021 in Japan. The decrease in our routine RT-PCR Ct values with 4 primer sets correlated with these fluctuations in lineage prevalence over time.Conclusions We confirmed that our RT-PCR protocol reflects the trends in SARS-CoV-2 variant prevalence over time regardless of sequence mutation. This may aid in the tracking of new variants in the population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Genesis Healthcare Corporation. The sponsor had no influence on the study other than providing resources and the facility.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected from volunteers, testing participants and patients under physician care undergoing clinical testing for SARS-CoV-2 (COVID-19). Samples were anonymized, and laboratory technicians and researchers were blinded to the identity of the patients. Only non-identifying data, such as age, sex and symptoms, were provided. All experimental protocols were approved by the ethics committee of Genesis Healthcare.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNGS data from the first and second COVIDseq runs were uploaded to GISAID.